RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions

Abstract: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Patent Number: US2016369283(A1)
Public Date:
Inventor: YANNI JOHN M [US]; CHATTERTON JON E [US]; SENCHYNA DIANE MICHELLE [US]; GAMACHE DANIEL A [US]; MILLE
Applicant: ARROWHEAD PHARMACEUTICALS INC [US]
Application Number: US201615255372 20160902Global Dossier
Application Date:
Priority Number: US201615255372 20160902;US201414244623 20140403;US201313973176 20130822;US201113035147 20110225;US20100700188 20100204;US20070750262 20070517;US20060801788P 20060519
International Classification: C12N15/113
Cooperative Classification: A61K31/7088; A61K31/713; C12N15/1137; C12N15/1138; C12N2310/14; C12N2310/346; C12N2310/351; C12N2320
Assignee:
Nation: